J Dermatol Sci 67:111119 Beck LA, Cork MJ, Amagai M, de Benedetto A, Kabashima K, Hamilton JD, Rossi AB (2022) Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
In a formal review, the agency concluded that BPC-157: Lacks sufficient safety data and has not been shown to be safe or effective in humans FDA Compounding Memorandum, 2023 The FDA also lists BPC-157 as ineligible for 503B compounding , which prohibits it from being added to compounded medications by outsourcing facilities
Patients with a history of suicidal ideation or attempts should be carefully evaluated before initiating treatment with Semaglutide / Cyanocobalamin Injection, as post-marketing reports have described occurrences of suicidal thoughts and behaviors in patients treated with GLP-1 receptor agonists
Med Hypotheses 143:110102 Yoshikawa T, Naito Y (2000) What is oxidative stress
and Closter, NJ.
It's not about targeting the cartilage directly, but about changing the entire environment of the injury to one that's conducive to healing
